

18 November 2024

Our Ref: FOI 283

Dear

**Freedom of Information Act 2000
Information in Relation to Patients treated for melanoma**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 21 October 2024.

A response to the questions you have raised has been provided by the Medicine, Unscheduled Care and Cancer Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Keith McCollum
Information Governance Team

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- **Cobimetinib**
- **Dabrafenib**
- **Dabrafenib + Trametinib**
- **Dacarbazine**
- **Denosumab**
- **Encorafenib + Binimetinib**
- **Ipilimumab monotherapy**
- **Ipilimumab + Nivolumab**
- **Nivolumab monotherapy**
- **Nivolumab + Relatlimab**
- **Pembrolizumab**
- **Trametinib**
- **Vemurafenib**
- **Vemurafenib + Cobimetinib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

A1. The Trust do not treat melanoma, therefore the Trust are unable to provide a response.

Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- **Ipilimumab monotherapy**
- **Ipilimumab + Nivolumab**
- **Nivolumab monotherapy**
- **Nivolumab + Relatlimab**
- **Pembrolizumab**
- **Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

A2. The Trust do not treat metastatic melanoma, therefore the Trust are unable to provide a response.

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

- ***Ipilimumab (monotherapy)***
- ***Nivolumab (monotherapy)***
- ***Nivolumab AND Ipilimumab (combination)***
- ***Nivolumab AND Relatlimab***
- ***Pembrolizumab***
- ***Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)***
- ***Other active systemic anti-cancer therapy***

****Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.***

A3. The Trust do not treat melanoma, therefore the Trust are unable to provide a response.